Table 1.
Study | Country | Study Design | Sample Size | Dates | Quality |
---|---|---|---|---|---|
Almazeedi et al63 (2020) | Kuwait | Retrospective cohort | 42 | 24/02-20/4/2020 | Good |
Amit et al64 (2020) | Israel | Chart review | 156 | 05/03-27/04/2020 | Good |
Arentz et al52 (2020) | United States | Case series | 21 | 20/02-05/03/2020 | Fair |
Auld et al53 (2020) | United States | Retrospective cohort | 217 | 06/03-17/04/2020 | Poor |
Barrasa et al20 (2020) | Spain | Prospective cohort | 48 | 04/03-24/03/2020 | Poor |
Bhatla et al54 (2020) | United States | Prospective cohort | 79 | 06/03-19/05/2020 | Good |
Bhatraju et al55 (2020) | United States | Case series | 24 | 24/02-09/03/2020 | Fair |
Borobia et al21 (2020) | Spain | Retrospective cohort | 75 | 25/02-19/04/2020 | Good |
Cardoso et al22 (2020) | Portugal | Case series | 20 | 10/03/2020 | Poor |
Chen et al37 (2020) | China | Retrospective case control subject | 51 | 22/01-25/03/2020 | Poor |
Cui et al38 (2020) | China | Case series | 81 | 30/01-22/03/2020 | Poor |
Cummings et al56 (2020) | United States | Prospective cohort | 257 | 02/03-01/04/2020 | Good |
Ferguson et al57 (2020) | United States | Chart review | 21 | 13/03-11/04/2020 | Poor |
Grasselli et al23 (2020) | Italy | Retrospective cohort | 1715 | 20/02-22/04/2020 | Poor |
Halasz et al24 (2020) | Italy | Case series | 242 | 02-04/2020 | Fair |
Halvatsiotis et al25 (2020) | Greece | Case series | 90 | 10/03-13/04/2020 | Fair |
Helms et al26 (2020) | France | Prospective cohort | 150 | 03/03-31/03/2020 | Good |
Hur et al58 (2020) | United States | Retrospective case control subject | 138 | 01/03-08/04/2020 | Good |
ICNARC et al27 (2020) | England | National clinical audit | 10624 | 01/03-30/07/2020 | … |
Khamis et al65 (2020) | Oman | Case series | 24 | 24/02-24/04/2020 | Poor |
Klok et al28,29 (2020) | Netherlands | Case series | 184 | 07/03-05/04/2020 | Poor |
Li J et al39 (2020) | China | Retrospective case control subject | 74 | 25/01-26/02/2020 | Poor |
Ling et al40 (2020) | China | Retrospective cohort | 8 | 22/01-11/02/2020 | Poor |
Llitjos et al30 (2020) | France | Retrospective case control subject | 26 | 19/03-11/04/2020 | Poor |
Longchamp et al31 (2020) | Switzerland | Case series | 25 | 08/03-04/04/2020 | Poor |
Maatman et al59 (2020) | United States | Retrospective cohort | 109 | 12/03-31/03/2020 | Poor |
Mitra et al60 (2020) | Canada | Case series | 117 | 21/02-14/04/2020 | Fair |
Myers et al61 (2020) | United States | Retrospective cohort | 113 | 01/03-31/03/2020 | Poor |
Pavoni et al32 (2020) | Italy | Case series | 40 | 28/02-10/04/2020 | Fair |
Pedersen et al33 (2020) | Denmark | Case series | 16 | 11/03-01/04/2020 | Poor |
Richardson et al62 (2020) | United States | Case series | 373 | 01/03-04/04/2020 | Fair |
Rodriguez et al34 (2020) | Spain | Prospective cohort | 43 | 14/03-16/04/2020 | Poor |
Simonnet et al35 (2020) | France | Retrospective cohort | 124 | 27/02-05/04/2020 | Good |
Thomas et al36 (2020) | United Kingdom | Case series | 63 | 15/03-14/04/2020 | Poor |
Wang Y et al41 (2020) | China | Case series | 344 | 25/01-25/02/2020 | Good |
Wei et al42 (2020) | China | Retrospective case control subject | 14 | 27/01-11/03/2020 | Poor |
Wu et al43 (2020) | China | Retrospective case control subject | 83 | 20/01-19/02/2020 | Good |
Xu B et al44 (2020) | China | Retrospective case control subject | 107 | 26/12-01/03/2020 | Good |
Xu J et al45 (2020) | China | Retrospective cohort | 239 | 12/01-03/02/2020 | Good |
Yang L et al46 (2020) | China | Retrospective case control subject | 29 | 30/01-08/02/2020 | Good |
Yu et al47 (2020) | China | Prospective cross-sectional | 226 | 26/02-26/02/2020 | Poor |
Zhang G et al48 (2020) | China | Case series | 55 | 02/01-10/02/2020 | Fair |
Zhang J et al49 (2020) | China | Case series | 19 | 16/01-20/02/2020 | Poor |
Zheng et al50 (2020) | China | Case series | 34 | 22/01-05/03/2020 | Fair |
Zhou Y et al51 (2020) | China | Retrospective case control subject | 21 | 28/01-02/03/2020 | Poor |